Neuroprotection and mechanisms of ginsenosides in nervous system diseases: Progress and perspectives
IUBMB Life · 2024
DOI: 10.1002/iub.2862 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift IUBMB Life, 2024. Verfasst von Li Zhou und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, Yan'an Hospital Affiliated to Kunming Medical University, Kunming, China. Hauptthemen laut MEDLINE: Ginsenosides, Neuroprotective Agents. Die Arbeit wurde bisher 49-mal zitiert (Crossref) und nennt 106 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Kunming Health Science and Technology "Thousand Project" Talents Project, Scientific Research Fund Project of Education Department of Yunnan Province.
Abstract (Originalsprache)
Ginsenosides are the primary component discernible from ginseng, including Rb1, Rb2, Rd, Rg1, Rg2, and compound K, and so forth. They have been shown to have multiple pharmacological activities. In recent years, more and more studies have been devoted to the neuroprotection of various ginsenosides against neurological diseases and their potential mechanisms. This paper comprehensively summarizes and reviews the neuroprotective effects of various ginsenosides on neurological diseases, especially acute and chronic neurodegenerative diseases, and their mechanisms, as well as their potential therapeutic applications to promote neuroprotection in disease prevention, treatment, and prognosis. Briefly, ginsenosides exert effective neuroprotective effects on neurological conditions, including stroke, Alzheimer's disease, Parkinson's disease, and brain/spinal cord injuries through a variety of molecular mechanisms, including anti‐inflammatory, antioxidant, and anti‐apoptotic. Among them, some signaling pathways play important roles in related processes, such as PI3K/Akt, TLR4/NF‐κB, ROS/TXNIP/NLRP3, HO‐1/Nrf2, Wnt/β‐catenin, and Ca 2+ pathway. In conclusion, the present study reviews the research progress on the neuroprotective effects of ginsenosides in the last decade, with the aim of furnishing essential theoretical underpinning and effective references for further research and exploration of the multiple medicinal values of Chinese herbal medicines and their small molecule compounds, including ginseng and panax ginseng. Because there is less evidence in the existing clinical studies, future research should be focused on clinical trials in order to truly reflect the clinical value of various ginsenosides for the benefit of patients.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmacy, Yan'an Hospital Affiliated to Kunming Medical University, Kunming, China.
ORCID-Profile: Wenjie Yin
Förderung
- Kunming Health Science and Technology "Thousand Project" Talents Project
- Scientific Research Fund Project of Education Department of Yunnan Province
Zitieren
APA
Zhou, L., Tan, F., Zhang, X., Li, Y., & Yin, W. (2024). Neuroprotection and mechanisms of ginsenosides in nervous system diseases: Progress and perspectives. IUBMB Life. https://doi.org/10.1002/iub.2862
Vancouver
Zhou L, Tan F, Zhang X, Li Y, Yin W. Neuroprotection and mechanisms of ginsenosides in nervous system diseases: Progress and perspectives. IUBMB Life. 2024. doi:10.1002/iub.2862
BibTeX
@article{Zhou2024,
author = {Zhou, Li and Tan, Feilong and Zhang, Xue and Li, Yanhua and Yin, Wenjie},
title = {Neuroprotection and mechanisms of ginsenosides in nervous system diseases: Progress and perspectives},
journal = {IUBMB Life},
year = {2024},
doi = {10.1002/iub.2862}
}
EUVIMED